Heart Failure
Conditions
Keywords
Apelin, Heart failure, Pulmonary artery pressure, Inotropic, Diuretic
Brief summary
The apelin-APJ system is a recently discover hormone system that has several important actions in the cardiovascular system. Apelin causes the heart pump with more force and also causes blood vessels to relax. Studies to date show that people with reduced pumping function of the heart have lower levels of apelin in the bloodstream compared to people with normal heart function. We have previously given apelin to healthy volunteers and people with reduced pumping function and this increases the heart's contraction. However, this has only been assessed over a short time period, around fifteen minutes, and we now want to know if this effect is seen over a longer period.
Interventions
DRUGApelin
Cardiac index will be assess in patients through the 6hr infusion, using thoracic cardiac bioimpedance. Prior to starting the infusion there will be a 30 minute run in period to achieve a stable cardiac index. Thereafter the infusion will be started, with cardiac index assess every five minutes during the first hour. For each subsequent hour participants will be free to mobilise for the thirty minute periods, with cardiac index and systemic haemodynmics assess for the following thirty minutes. Additionally during the first hour pulmonary artery pressure will be estimated from pulmonary artery pressures assessed with echocardiography. This will be assessed at baseline with four further measurements during the first hour of infusion. Participants will be asked to void prior to the study starting, thereafter all urine will be collected during the course of the study. Relevant biochemical/humoral factors will be assessed in the urine.
DRUGPlacebo
As per apelin arm, however we will use a saline placebo infusion. All other aspects will remain the same.
Sponsors
University of Edinburgh
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
Healthy volunteers: \>18yrs Heart failure patients; * New York Heart Failure class II-IV * Ejection fractional \<35% or fractional shortening \<20% within previous 6months.
Exclusion criteria
All subjects, * Females of child bearing age not on adequate contraception * Lack of informed consent * Age \<18yrs * Current involvement in any other research study * Systolic BP \>190 or \<100 * Malignant arrhythmias * Renal or hepatic failure * Haemodynamically significant aortic stenosis * Severe or significant co-morbidity * Pacemakers Healthy volunteers * Any regular medication * Previous history of any cardiovascular disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| cardiac output | 6 hours | We will assess, using thoracic bioimpedance cardiography, the change in cardiac output in response to apelin infusion |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Urine volume | 6 hours | All urine will be collected during the studya and we will assess volume and relevant biochemical/humoral factors |
| Pulmonary artery pressure | 1 hour | Using echocardiography we will estimate the pulmaonary artery pressure from pulmonary velocity and assess any change during the first hour of study. |
Countries
United Kingdom
Outcome results
None listed